CORE BIOSTATISTICS will reside within the University of Pittsburgh Cancer Institute's (UPCI) Biostatistics Facility, which provides clinical and basic-science investigators in UPCI with statistical and computer-related expertise in design, execution, analysis, and reporting of cancer-related research studies. These cover basic-science studies;phase I and phase II oncology clinical trials;epidemiologic studies, including those related to cancer prevention and awareness;and investigations of behavioral and health sequellae of cancer treatment. In its role as Core for this Program Project, the Biostatistics Core will support all three Projects with respect to statistical aspects of study design and data analysis, and contribute as well to statistical aspects of quality control and assay quantitation in the IMCPL / Flow Cytometry Core. Specifically, the Biostatistics Core will collaborate with the Program-Project investigators on statistical aspects of the design of the laboratory-based studies as new data come to light, and perform both exploratory and confirmatory statistical analyses of the resulting data from key experiments;collaborate on developing final versions of protocols for the clinical trials that are planned;perform interim analyses of safety for the Program Project's clinical trials, and final analyses of safety, immune response, and efficacy; work with investigators to ensure that data collection and reporting of the laboratory-based data and clinical trial data are appropriate for the requisite statistical analyses;establish databases that link laboratory-based data and clinical-trial data where needed;provide consultation to investigators on issues of quality control and assay quantitation for laboratory-based studies;and collaborate with investigators in writing and preparing progress reports, abstracts, manuscripts, and presentations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA109688-05
Application #
8121430
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2010-08-01
Budget End
2011-07-31
Support Year
5
Fiscal Year
2010
Total Cost
$80,395
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Spitler, Lynn E; Cao, Huynh; Piironen, Timo et al. (2017) Biological Effects of Anti-Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Antibody Formation in Patients Treated With GM-CSF (Sargramostim) as Adjuvant Therapy of Melanoma. Am J Clin Oncol 40:207-213
Macatangay, Bernard J C; Riddler, Sharon A; Wheeler, Nicole D et al. (2016) Therapeutic Vaccination With Dendritic Cells Loaded With Autologous HIV Type 1-Infected Apoptotic Cells. J Infect Dis 213:1400-9
Szczepanski, Miroslaw J; Luczak, Michal; Olszewska, Ewa et al. (2015) Molecular signaling of the HMGB1/RAGE axis contributes to cholesteatoma pathogenesis. J Mol Med (Berl) 93:305-14
Whiteside, Theresa L (2015) Clinical Impact of Regulatory T cells (Treg) in Cancer and HIV. Cancer Microenviron 8:201-7
Schuler, P J; Saze, Z; Hong, C-S et al. (2014) Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells. Clin Exp Immunol 177:531-43
Schuler, Patrick J; Harasymczuk, Malgorzata; Visus, Carmen et al. (2014) Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clin Cancer Res 20:2433-44
Whiteside, Theresa L (2014) Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression? Cancer Immunol Immunother 63:67-72
Schuler, Patrick J; Macatangay, Bernard J C; Saze, Zenichiro et al. (2013) CD4?CD73? T cells are associated with lower T-cell activation and C reactive protein levels and are depleted in HIV-1 infection regardless of viral suppression. AIDS 27:1545-55
Harasymczuk, Malgorzata; Gooding, William; Kruk-Zagajewska, Aleksandra et al. (2013) Head and neck squamous carcinomas with exophytic and endophytic type of growth have the same prognosis after surgery and adjuvant radiotherapy. Eur Arch Otorhinolaryngol 270:1105-14
Schilling, Bastian; Harasymczuk, Malgorzata; Schuler, Patrick et al. (2013) IRX-2, a novel immunotherapeutic, enhances functions of human dendritic cells. PLoS One 8:e47234

Showing the most recent 10 out of 110 publications